You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 7,229,620


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,229,620
Title:Method for radiolabeling antibodies with yttrium-90
Abstract: Methods and kits for radiolabeling proteins, peptides and ligands with radiolytic isotopes, particularly yttrium-90, are disclosed, whereby sufficient purity, specific activity and binding affinity are achieved such that the radiolabeled protein may be directly administered to a patient without further column purification. Such kits and methods will be particularly useful in bringing radioimmunotherapy to the hospital and outpatient setting for the treatment of cancer.
Inventor(s): Chinn; Paul (Carlsbad, CA)
Assignee: Biogen Idec Inc. (Cambridge, MA)
Application Number:11/181,811
Patent Claims:1. A method for radiolabeling a chelator-conjugated antibody or antibody fragment with .sup.90Y for administration to a patient comprising: (i) mixing the chelator-conjugated antibody or antibody fragment with a solution comprising .sup.90Y or a salt thereof, and (ii) incubating the mixture for a sufficient amount of time under amiable conditions such that a .sup.90Y-labeled antibody or antibody fragment is produced having sufficient radioincorporation, immunoreactivity of at least 50%, and a specific activity of at least about 5 mCi/mg, such that the .sup.90Y-labeled antibody or antibody fragment may be administered directly to the patient without further purification of the .sup.90Y-labeled radiolabeled antibody or antibody fragment from unincorporated .sup.90Y; wherein said chelator is a bifunctional chelator selected from the group consisting of MX-DTPA, phenyl-DTPA, benzyl-DTPA, CHX-DTPA, DOTA and derivatives thereof.

2. The method of claim 1, wherein said amiable conditions refer to acceptable temperature, pH and buffer conditions.

3. The method of claim 2, wherein said acceptable temperature ranges from about 25.degree. C. to about 50.degree. C.

4. The method of claim 2, wherein said acceptable pH ranges from about 3 to about 6.

5. The method of claim 2, wherein said acceptable buffer is an acetate buffer and is at a concentration of between about 10 and about 1000 mM.

6. The method of claim 1, wherein said sufficient incubation time is less than about eight minutes.

7. The method of claim 6, wherein said sufficient incubation time is between about 30 seconds to about five minutes.

8. The method of claim 1, wherein the specific activity of the .sup.90Y-labeled antibody or antibody fragment is greater than 10 mCi/mg.

9. The method of claim 8, wherein the specific activity of the .sup.90Y-labeled antibody or antibody fragment is at least 15 mCimg.

10. The method of claim 1, wherein a level of radioincorporation of greater than 95% is achieved.

11. The method of claim 1, wherein a level of radioincorporation of greater than 96% is achieved.

12. The method of claim 1, wherein the immunoreactivity is at least 70%.

13. The method of claim 1, wherein the immunoreactivity is at least 80%.

14. The method of claim 1, wherein the chelator is MX-DTPA.

15. The method of claim 1, wherein the ratio of chelator to antibody or antibody fragment ranges from 11/2 to 1.

16. The method of claim 1, wherein the antibody or antibody fragment binds specifically to CD20.

17. The method of claim 16, wherein the antibody is 2B8.

18. The method of claim 17, wherein the chelator is MX-DTPA.

19. The method of claim 1, wherein the antibody fragment is selected from the group consisting of Fab, F(ab').sub.2, and Fv fragments.

20. A method for radiolabeling a MX-DTPA-conjugated 2B8 antibody or antibody fragment with .sup.90Y for administration to a patient comprising: (i) mixing the MX-DTPA-conjugated antibody or antibody fragment with a solution comprising .sup.90Y or a salt thereof, and (ii) incubating the mixture for a sufficient amount of time under acceptable temperature, pH and buffer conditions such that a .sup.90Y-labeled antibody or antibody fragment is produced having sufficient radioincorporation, immunoreactivity of at least 50% , and a specific activity of at least about 5 mCi/mg, such that the .sup.90Y-labeled antibody or antibody fragment may be administered directly to the patient without further purification of the .sup.90Y-labeled 2B8 antibody or antibody fragment from unincorporated .sup.90Y.

International Patent Family for US Patent 7,229,620

Country Patent Number Estimated Expiration
South Africa 200106945 ⤷  Try a Trial
Yugoslavia 61701 ⤷  Try a Trial
World Intellectual Property Organization (WIPO) 0052031 ⤷  Try a Trial
United States of America 7618613 ⤷  Try a Trial
United States of America 6994840 ⤷  Try a Trial
United States of America 2007297978 ⤷  Try a Trial
United States of America 2006067884 ⤷  Try a Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.